New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
16:25 EDTMYL, SNTSSantarus discloses lawsuit against Mylan for patent infringement
Santarus disclosed in a regulatory filing that on January 28, Santarus (SNTS) filed a lawsuit in the U.S. District Court for the District of Delaware against Mylan (MYL) and Mylan Pharmaceuticals for infringement of the patents listed in the Orange Book for Santarusí prescription product, Fenoglide tablets, 40 mg and 120 mg. Veloxis Pharmaceuticals A/S, licensor of the patents, is joined in the litigation as a co-plaintiff. The lawsuit is in response to an Abbreviated New Drug Application filed by Mylan with the U.S. FDA regarding Mylanís intent to market generic versions of Fenoglide prior to the 2024 expiration of the two listed patents. The lawsuit was commenced within the 45 days required to automatically stay, or bar, the FDA from approving Mylanís ANDA for 30 months or until a district court decision that is adverse to the plaintiffs, whichever may occur earlier.
News For SNTS;MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
06:04 EDTMYLMylan and Perrigo set to face-off over potential targets, Bloomberg reports
Mylan (MYL) will likely find itself now competing with Perrigo (PRGO) for other assets, reports Bloomberg. According to Bloomberg Intelligence analyst Elizabeth Krutoholow, both companies may look to buy Impax Laboratories (IPXL), Stada Arzneimittel or Taro Pharmaceutical Industries (TARO). All of the potential targets are attractive due to their over-the-counter products. Reference Link
November 24, 2015
07:33 EDTMYLMylan launches Clozapine Orally Disintegrating Tablets in the U.S.
Mylan (MYL) announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo (JAZZ). Mylan received final approval from the FDA for its Abbreviated New Drug Application, or ANDA, for this product, which is used for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment.
November 20, 2015
07:32 EDTMYLMylan completes acquisition of certain businesses from Famy Care
Subscribe for More Information
November 19, 2015
15:29 EDTMYLMylan confirms first-to-file patent challenge relating to Delzicol
Subscribe for More Information
13:52 EDTMYLMylan announces U.S. launch of generic Adderall tablets
Subscribe for More Information
November 18, 2015
08:22 EDTMYLMylan resinstated with an Overweight at JPMorgan
Subscribe for More Information
06:02 EDTMYLPerrigo upgraded to Buy from Neutral at B. Riley
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use